mCRC Education
Metastatic colorectal cancer treatment is evolving rapidly — from biomarker-driven therapy selection to emerging immunotherapy combinations. Knowledge Med sessions put community providers at the center of mCRC case simulations, building confidence in molecular profiling, sequencing decisions, and managing treatment-related toxicities.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing metastatic colorectal cancer face evolving treatment decisions that interactive, independently reviewed education can help address.
- Interpreting RAS/BRAF/MSI biomarker results to guide therapy selection
- Sequencing targeted therapies and immunotherapy in later lines
- Managing EGFR inhibitor-related dermatologic toxicities
- Identifying candidates for hepatic metastasectomy and local therapies
What Sessions Cover
Knowledge Med mCRC sessions use interactive case simulations to address these topics and more.
- Biomarker-driven first-line therapy selection in mCRC
- Left-sided vs right-sided tumor biology and treatment implications
- Immunotherapy in MSI-H/dMMR colorectal cancer
- Managing treatment sequencing after progression on first-line therapy
Interactive mCRC Sessions
Case Simulations
Work through realistic metastatic colorectal cancer patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key mCRC clinical takeaways.
More Solid Tumor Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
HER2-Positive Breast Cancer
HER2+ — First-line treatment selection in HER2+ metastatic breast cancer
Metastatic Breast Cancer
mBC — First-line endocrine-based therapy selection in HR+/HER2- mBC
Triple-Negative Breast Cancer
TNBC — Immunotherapy in first-line metastatic TNBC: patient selection and regimens
Non-Small Cell Lung Cancer
NSCLC — Biomarker-driven first-line therapy selection in advanced NSCLC
Join a mCRC Session
Third-party, non-promotional metastatic colorectal cancer education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session